TipRanks
Advertisement
Advertisement

RLAY Stock Latest News

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
TipRanks NewswireNuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
29d ago
AZN
NVS
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
PremiumThe Fly
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
2M ago
RLAY
Relay Therapeutics price target raised to $31 from $28 at JPMorgan
PremiumThe Fly
Relay Therapeutics price target raised to $31 from $28 at JPMorgan
2M ago
RLAY
Relay Therapeutics price target raised to $25 from $21 at BofA
PremiumThe Fly
Relay Therapeutics price target raised to $25 from $21 at BofA
3M ago
RLAY
Relay Therapeutics price target raised to $26 from $21 at Citizens
PremiumThe Fly
Relay Therapeutics price target raised to $26 from $21 at Citizens
3M ago
RLAY
Relay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts
PremiumRatingsRelay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts
3M ago
RLAY
Boris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward
Premium
Ratings
Boris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward
3M ago
RLAY
Relay Therapeutics price target raised to $30 from $27 at Barclays
Premium
The Fly
Relay Therapeutics price target raised to $30 from $27 at Barclays
3M ago
RLAY
Analyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029
PremiumRatings
Analyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029
3M ago
RLAY
Relay Therapeutics Expands ATM Equity Offering Agreement
PremiumCompany Announcements
Relay Therapeutics Expands ATM Equity Offering Agreement
3M ago
8K
RLAY
Private Markets: Chai Discovery, Etched land major rounds
PremiumThe Fly
Private Markets: Chai Discovery, Etched land major rounds
3M ago
J
AI
Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs
PremiumThe Fly
Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs
3M ago
RLAY
Relay Therapeutics initiated with a Buy at Canaccord on zovegalisib’s potential
PremiumThe FlyRelay Therapeutics initiated with a Buy at Canaccord on zovegalisib’s potential
3M ago
RLAY
Relay Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Relay Therapeutics initiated with a Buy at Canaccord
3M ago
RLAY
Relay Therapeutics initiated with an Overweight at JPMorgan
Premium
The Fly
Relay Therapeutics initiated with an Overweight at JPMorgan
4M ago
RLAY
Relay Therapeutics: Buy Rating on Undervalued Zovegalisib Franchise with Multi‑Billion Peak Sales Potential in Breast Cancer and Vascular Anomalies
PremiumRatings
Relay Therapeutics: Buy Rating on Undervalued Zovegalisib Franchise with Multi‑Billion Peak Sales Potential in Breast Cancer and Vascular Anomalies
4M ago
RLAY
Relay Therapeutics Targets NRAS Cancers With New First-in-Human Trial
PremiumCompany Announcements
Relay Therapeutics Targets NRAS Cancers With New First-in-Human Trial
4M ago
RLAY
Relay Therapeutics Expands Authorized Shares at 2026 Meeting
PremiumCompany Announcements
Relay Therapeutics Expands Authorized Shares at 2026 Meeting
5M ago
8K
RLAY
Relay Therapeutics price target raised to $26 from $22 at Guggenheim
PremiumThe Fly
Relay Therapeutics price target raised to $26 from $22 at Guggenheim
5M ago
RLAY
Relay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
PremiumThe FlyRelay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
5M ago
RLAY
Citizens biotech analysts hold a dinnermeeting at ASCO
Premium
The Fly
Citizens biotech analysts hold a dinnermeeting at ASCO
5M ago
AZN
LLY
Relay Therapeutics Announces Major Underwritten Equity Offering
Premium
Company Announcements
Relay Therapeutics Announces Major Underwritten Equity Offering
5M ago
8K
RLAY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >